📊 LGVN Key Takeaways
Is Longeveron Inc. (LGVN) a Good Investment?
Longeveron exhibits severe operational deterioration with 50% YoY revenue collapse and $4.8M operating losses on $398K revenue, indicating fundamental commercialization failure. Despite a fortress balance sheet ($15.8M cash, $143K debt), the company is burning $4.4M annually with only 3-4 years of runway and zero visible path to profitability or revenue recovery.
Longeveron exhibits minimal revenue with a high gross margin but suffers from extremely negative operating and net margins, reflecting a pre-commercial, cash-consuming profile. With only $4.66M in cash versus roughly $18.6M in annual operating outflows and a modest 1.33x current ratio, liquidity is thin and raises near-term dilution or going-concern risk. Low leverage is a positive, but the 49.9% YoY revenue decline and persistent losses overshadow strengths.
Longeveron Inc. Key Strengths (LGVN)
- Strong balance sheet with $15.8M cash versus $143K long-term debt
- Excellent liquidity position with 3.88x current ratio providing operational buffer
- High gross margin of 66.3% suggests healthy product economics on limited revenue base
- Low financial leverage (Debt/Equity 0.03x)
- High gross margin on limited revenue (67%)
- Low capex requirements supporting flexible spending (CapEx $245K)
LGVN Stock Risks: Longeveron Inc. Investment Risks
- Revenue collapsed 49.9% YoY indicating failed product commercialization or market rejection
- Operating cash burn of $4.4M annually with operating losses of $4.8M on minimal revenue
- Limited runway of 3-4 years at current burn despite strong balance sheet
- Negative ROE (-29.6%) and ROA (-22.3%) showing value destruction
- No meaningful capital expenditure despite pharmaceutical sector requirements for R&D
- Severe cash burn with limited cash balance implying near-term financing/dilution risk
- Extremely negative profitability (Operating margin -1942%, Net margin -1894%)
- Revenue contraction (-49.9% YoY) increases going-concern risk and execution uncertainty
Key Metrics to Watch
- Quarterly revenue trend for stabilization or inflection
- Operating cash flow trajectory and sustainability of burn rate
- Cash balance depletion timeline and covenant compliance
- Clinical trial outcomes and regulatory approval status for pipeline products
- Gross margin sustainability on lower revenue base
- Cash and equivalents
- Operating cash flow (burn rate)
Longeveron Inc. (LGVN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.88x current ratio provides a solid financial cushion.
LGVN Profit Margin, ROE & Profitability Analysis
LGVN vs Healthcare Sector: How Longeveron Inc. Compares
How Longeveron Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Longeveron Inc. Stock Overvalued? LGVN Valuation Analysis 2026
Based on fundamental analysis, Longeveron Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Longeveron Inc. Balance Sheet: LGVN Debt, Cash & Liquidity
LGVN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Longeveron Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.62 indicates the company is currently unprofitable.
LGVN Revenue Growth, EPS Growth & YoY Performance
LGVN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $381.0K | -$4.7M | $-0.19 |
| Q3 2025 | $137.0K | -$4.4M | $-0.34 |
| Q2 2025 | $316.0K | -$3.4M | $-0.33 |
| Q1 2025 | $381.0K | -$4.1M | $-0.34 |
| Q3 2024 | $150.0K | -$4.4M | $-0.34 |
| Q2 2024 | $217.0K | -$3.4M | $-1.83 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Longeveron Inc. Dividends, Buybacks & Capital Allocation
LGVN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Longeveron Inc. (CIK: 0001721484)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LGVN
What is the AI rating for LGVN?
Longeveron Inc. (LGVN) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LGVN's key strengths?
Claude: Strong balance sheet with $15.8M cash versus $143K long-term debt. Excellent liquidity position with 3.88x current ratio providing operational buffer. ChatGPT: Low financial leverage (Debt/Equity 0.03x). High gross margin on limited revenue (67%).
What are the risks of investing in LGVN?
Claude: Revenue collapsed 49.9% YoY indicating failed product commercialization or market rejection. Operating cash burn of $4.4M annually with operating losses of $4.8M on minimal revenue. ChatGPT: Severe cash burn with limited cash balance implying near-term financing/dilution risk. Extremely negative profitability (Operating margin -1942%, Net margin -1894%).
What is LGVN's revenue and growth?
Longeveron Inc. reported revenue of $398.0K.
Does LGVN pay dividends?
Longeveron Inc. does not currently pay dividends.
Where can I find LGVN SEC filings?
Official SEC filings for Longeveron Inc. (CIK: 0001721484) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LGVN's EPS?
Longeveron Inc. has a diluted EPS of $-0.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is LGVN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Longeveron Inc. has a D grade with 82% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is LGVN stock overvalued or undervalued?
Valuation metrics for LGVN: ROE of -29.6% (sector avg: 15%), net margin of -1,189.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is LGVN's AI grade for 2026?
Our dual AI analysis gives Longeveron Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LGVN's free cash flow?
Longeveron Inc.'s operating cash flow is $-4.4M, with capital expenditures of $0.0. FCF margin is -1,098.0%.
How does LGVN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,189.9% (avg: 12%), ROE -29.6% (avg: 15%), current ratio 3.88 (avg: 2).